Skip to main content

Advertisement

Table 1 Clinical characteristics in T1G3 patients treated with BCG

From: Expression level of dihydropyrimidine dehydrogenase is associated with clinical outcome in patients with T1G3 bladder cancer treated with Bacillus Calmette-Guerin

  Overall
Age, mean ± SE 66.9 ± 2.3
Gender, men/women 23 (82.1%)/5 (17.9%)
Concomitant CIS 7 (25.0%)
Multiple disease 19 (67.9%)
LVI positive 18 (64.3%)
Recurrence 13 (46.4%)
Progression 5 (17.9%)
Death 1 (2.2%)
Disease specific death 0 (0.0%)
  1. SE: standard error; CIS: carcinoma in situ; LVI: lymphovascular invasion.